SITC Names 2026 Fellows to Academy of Immuno-Oncology
Milwaukee, Wisconsin, August 17, 2026 The Society for Immunotherapy of Cancer (SITC) has announced the 2026 Class of Fellows...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Milwaukee, Wisconsin, August 17, 2026 The Society for Immunotherapy of Cancer (SITC) has announced the 2026 Class of Fellows...
HOUSTON, June 1, 2026 Iterion Therapeutics has unveiled compelling clinical data supporting tegavivint, its first-in-class Wnt/β-catenin pathway inhibitor, as...
SANTA CLARA, Calif., June 1, 2026 Agilent Technologies and Sound Analytics have announced a strategic collaboration aimed at transforming...
MONTEVIDEO, Uruguay & NEW YORK, United States, April 7, 2026 Resolve Therapeutics and the Institut Pasteur de Montevideo announced...
South San Francisco, Calif. – October 30, 2025 — BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations at...
